← Back to Search

Magnetic Resonance Spectroscopy

MRS Brain Imaging for Normal Brain Function

N/A
Recruiting
Led By Li An, Ph.D.
Research Sponsored by National Institute of Mental Health (NIMH)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18-65 years of age
Be older than 18 years old
Must not have
History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson's disease, seizure disorder or traumatic brain injury
Serious medical illness as determined from H&P or laboratory testing including Diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up prospective and ongoing
Awards & highlights
No Placebo-Only Group

Summary

This trial will use magnetic resonance spectroscopy to study how the brain metabolizes glucose into specific chemical transmitters. This will help researchers understand how different neurotransmitters are produced.

Who is the study for?
This trial is for healthy adults aged 18-65 who can consent to participate. They must be enrolled in specific protocols, have no serious medical conditions, not use certain psychotropic drugs or substances, and cannot be pregnant or breastfeeding. People with metal implants affected by MRI or claustrophobia are also excluded.
What is being tested?
The study uses advanced MRS technology at different strengths (3T and 7T) to track how the brain processes glucose into neurotransmitters like glutamate and GABA. It's a non-invasive way to understand brain metabolism in healthy individuals.
What are the potential side effects?
Since this study involves MRS scans which are similar to MRIs, side effects might include discomfort from lying still during the scan or anxiety due to being in an enclosed space. There's no exposure to radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have a history of major neurological illnesses like MS, Parkinson's, seizures, or brain injuries.
Select...
I have a serious illness like diabetes.
Select...
I cannot lie flat for over two hours.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~prospective and ongoing
This trial's timeline: 3 weeks for screening, Varies for treatment, and prospective and ongoing for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The is the quality of the MR spectroscopy which includes spectrum signal-to-noise (SNR)\ ratio, spectral lineshape, linewidth, and resolution.
Secondary study objectives
The is the performance improvements of the scanner hardware, software and methodology

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: One armExperimental Treatment1 Intervention
Subjects receive the same test

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)Lead Sponsor
2,933 Previous Clinical Trials
2,741,278 Total Patients Enrolled
5 Trials studying Normal Physiology
3,727 Patients Enrolled for Normal Physiology
Li An, Ph.D.Principal InvestigatorNational Institute of Mental Health (NIMH)
1 Previous Clinical Trials
300 Total Patients Enrolled
Steve Li, Ph.D.Principal InvestigatorNational Institute of Mental Health (NIMH)
1 Previous Clinical Trials
300 Total Patients Enrolled

Media Library

MRS (Magnetic Resonance Spectroscopy) Clinical Trial Eligibility Overview. Trial Name: NCT00109174 — N/A
Normal Physiology Research Study Groups: One arm
Normal Physiology Clinical Trial 2023: MRS Highlights & Side Effects. Trial Name: NCT00109174 — N/A
MRS (Magnetic Resonance Spectroscopy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00109174 — N/A
~43 spots leftby Jan 2030